Clinical pharmacokinetics of cerivastatin

Clinical Pharmacokinetics

Volumn 39, Issue 2, 2000, Pages 99-116

  Muck, W ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; CIMETIDINE; CLOFIBRATE; COLESTYRAMINE; DIGITOXIN; DRUG METABOLITE; FUROSEMIDE; GEMFIBROZIL; GLIBENCLAMIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IBUPROFEN; IMIPRAMINE; NICOTINIC ACID; NIFEDIPINE; OMEPRAZOLE; PHENYLBUTAZONE; PHENYTOIN; PROPRANOLOL; PROTON PUMP INHIBITOR; PYRIDINE DERIVATIVE; SALICYLIC ACID; WARFARIN;

ADULT; AGED; AREA UNDER THE CURVE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; FEMALE; FIRST PASS EFFECT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW;

EID: 0033831429     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200039020-00002     Document Type: Review

References (84)

1. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. BAY w 6228
5. Cerivastatin
6. Extending therapy options in treating lipid disorders: A clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor
7. Efficacy and safety of 300μg and 400μg cerivastatin once daily in patients with primary hypercholesterolaemia: A multicentre, randomized, double-blind, placebo-controlled study
8. A pooled efficacy analysis of cerivastatin in the treatment of hyperlipidemia
9. Cerivastatin: Pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor
10. Preclinical review of cerivastatin sodium: A step forward in HMG-CoA reductase inhibition
11. Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor
12. Cerivastatin, a new inhibitor of HMG-CoA reductase: Pharmacokinetics in rats and dogs
13. Preclinical and clinical pharmacology of cerivastatin
14. Cerivastatin (BAY w 6228): A novel HMG-CoA reductase inhibitor
15. Current and future treatment of hyperlipidemia: The role of statins
16. Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor; effect of 0.2mg daily in subjects with primary hypercholesterolemia
17. Differentiation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors by their relative lipophilicity
18. Determination of rivastatin in plasma by GC with double derivatization
19. Determination of rivastatin levels in plasma samples by HPLC and enzyme inhibition assay
20. LC separation and induced fluorometric detection of rivastatin in blood plasma
21. Quantitation of cerivastatin and its seven acid and lactone biotransformation products in human serum by liquid chromatography-electrospray tandem mass spectrometry
22. Effect of itraconazole on cerivastatin pharmacokinetics
23. Biopharmaceutical profile of cerivastatin: A novel HMG-CoA reductase inhibitor
24. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin
25. Cryopreserved human hepatocytes as a tool for the prediction of in vivo transport and transport-mediated drug-drug interactions
26. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors
27. 14C]BAY w 6228: Biotransformation in human liver microsomes in vitro. Characterization of primary metabolite pathways and of cytochrome P450 isozymes involved
28. Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or evening
29. Influence of cholestyramine on the pharmacokinetics of cerivastatin
30. Lack of pharmacokinetic drug-drug interaction, between orlistat and cerivastatin
31. No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin
32. Minor alterations in cerivastatin pharmacokinetics by erythromycin and itraconazole
33. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia
34. Interethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin
35. Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers
36. Pharmacokinetics, safety and tolerability of multiple-dose cerivastatin in males and females - A double-blind study
37. Phase I study of an antihyperlipidaemic BAY w 6228 (cerivastatin sodium) (1): Results of single administration studies in healthy adult male volunteers
38. Phase I study of an antihyperlipidaemic BAY w 6228 (cerivastatin sodium) (2): Results of multiple administration studies in healthy adult male volunteers
39. A clinical trial of pharmacokinetics of BAY w 6228 in elderly volunteers
40. Effects of hepatic and renal impairment on pharmacokinetics and pharmacodynamics of atorvastatin
41. Interactions with hydroxy-methylglutaryl-coenzyme A reductase inhibitors
42. Influence of renal function on the pharmacokinetics of cerivastatin in normocholesterolemic adults
43. Pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance
44. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions
45. 2-antagonist cimetidine on the pharmacokinetics of cerivastatin
46. Lack of drug-drug interaction between cerivastatin and omeprazole
47. Drug interactions of lipid-altering drugs
48. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin
49. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: Linking in vitro with in vivo information
50. Inhibition of hepatic cytochrome P450 isoform CYP3A by 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors
51. Lack of drug-drug interaction between cerivastatin and nifedipine
52. Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers
53. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy
54. Dual hepatic metabolism of cerivastatin: Clarifications
55. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
56. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients
57. Cerivastatin: Concept of microdoses and reduced interactions
58. Clinical efficacy and safety of cerivastatin: Summary of pivotal phase IIb/III studies
59. Cerivastatin in primary hyperlipidemia: A multicenter analysis of efficacy and safety
60. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors
61. P-glycoprotein-mediated apical secretion of atorvastatin in caco-2 cell monolayers
62. Interaction of HMG-CoA reductase inhibitors with members of the organic anion transporter family
63. Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells
64. Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors
65. The pleiotropic effects of drugs affecting lipid metabolism
66. Pharmacological effects of HMG-CoA reductase inhibitors other than lipoprotein modulation
67. Clinical pharmacokinetics of 3-hydroxy-3methylglutaryl-coenzmye A reductase inhibitors
68. Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidemia
69. Atorvastatin: A hydroxymethylglutaryl-coenzyme A reductase inhibitor
70. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin
71. Microstatins: A new generation of potent cholesterol biosynthesis inhibitors with a reduced interaction potential. Focus on cerivastatin
72. Effect of itraconazole on the pharmacokinetics of atorvastatin
73. Mibefradil significantly increases serum concentrations of atorvastatin but not pravastatin
74. Grapefruit juice increases serum simvastatin and atorvastatin but not pravastatin
75. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
76. Effects of erythromycin on plasma fluvastatin levels: A pharmacokinetic study
77. Clinical pharmacokinetics of mibefradil
78. Differences in metabolism of lovastatin and pravastatin as assessed by CYP3A inhibition with erythromycin
79. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid
80. Simvastatin but not inhibitor itraconazole
81. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
82. Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors
83. Cerivastatin and atorvastatin: Efficacy, safety and drug-interaction of the new HMG-CoA reductase inhibitors in renal transplant recipients